Dover Corporation (DOV) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 is constructive — management explicitly guided to the top end of the full-year range at Q1 earnings, record Q1 bookings of $2.5B (book-to-bill 1.2x) provide strong revenue visibility, and broad peer commentary confirms robust demand in DOV's key secular growth markets (data centers, biopharma, A&D); the primary risk is whether the stock — down ~6% since Q1 earnings vs. XLI +2.7% and SPY +5.5% — has already priced in a beat or if the underperformance creates a favorable setup.

Dover heads into Q2 2026 earnings with one of the strongest demand backdrops in recent memory: Q1 bookings hit a record $2.5B, up 24% YoY, with book-to-bill of 1.2x across all five segments, and management explicitly stated they are “driving to the top end of the range” and would revisit top-line guidance if bookings trends hold. Consensus expects revenue of ~$2.21B (organic growth ~5.3%) and adjusted EPS of ~$2.46, both representing meaningful step-ups from Q1 actuals of $2.05B and $2.03, consistent with DOV’s typical Q2 seasonal strength. Estimate revisions have been modestly positive since Q1 earnings — EPS consensus for Q2 moved from $2.39 to $2.46 — suggesting the Street has partially incorporated management’s bullish tone but has not fully extrapolated the record bookings into the revenue line. The stock has underperformed XLI by ~9.7 percentage points since Q1 earnings (DOV -6% vs. XLI +2.7%), which may reflect macro uncertainty or simply sector rotation, but creates a potentially favorable setup if the print confirms the bookings-to-revenue conversion management signaled. The key wildcard is the Climate & Sustainability Technologies segment: management flagged a refrigeration facility consolidation running ~one quarter behind schedule, with a material margin inflection expected in H2 once consolidation completes by mid-year — if this drag persists into Q2, it could weigh on segment margins even as top-line growth remains strong.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a moderately high bar on revenue (~$2.21B, +7.7% YoY) and EPS (~$2.46, +11.4% YoY), but the record Q1 bookings and management’s explicit top-of-range guidance signal the bar is achievable; bookings and book-to-bill are the most important swing factors for the stock reaction.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha consensus data. Q2 2026 actuals not yet reported. Book-to-bill and bookings consensus are key leading indicators — Q1’s record 1.2x book-to-bill and $2.5B bookings set a high bar for sequential comparison.

Table 2 — Beat/Miss History (Last 8 Quarters, Top 2 KPIs)

Revenue Beat/Miss:

Adjusted EPS Beat/Miss:

DOV has beaten adjusted EPS consensus in each of the last 7 reported quarters, with an average beat of ~3.8%. Revenue beats are less consistent (4 beats, 3 misses in last 7 quarters), suggesting margin execution is more reliable than top-line outperformance.

3. Guidance & Commentary Evolution

Key Takeaway: Management’s tone shifted decisively bullish at Q1 earnings — from “reaffirming guidance” to explicitly “driving to the top end of the range” — and no post-earnings guidance revision events have occurred since April 23; the key question is whether Q2 results trigger the upward top-line revision management telegraphed.

Note: No post-earnings 8-K guidance updates or investor conference revisions were filed between April 23 and July 22, 2026. The May 12 shareholder vote (rejection of independent board chair proposal) was a governance event with no financial guidance implications.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: EPS estimates for Q2 2026 have moved up ~2.9% since Q1 earnings (from $2.39 to $2.46), reflecting management’s bullish tone, while FY EPS consensus has also drifted higher; revenue estimates for Q2 are essentially flat since Q1 earnings, suggesting the Street has been more conservative on the top line despite record bookings.

* The notable gap between FY adjusted EPS consensus (~$9.70) and management guidance midpoint ($10.55) likely reflects a definitional difference (GAAP vs. operating/adjusted excluding amortization). Management’s $10.45–$10.65 guidance is on an adjusted basis excluding acquisition-related amortization; consensus may be on a different basis. The Q2 EPS revision of +2.9% since Q1 earnings is the most meaningful signal — the Street has incrementally raised the bar.

5. Stock Performance

Key Takeaway: DOV has significantly underperformed both XLI (+2.7%) and SPY (+5.5%) since Q1 earnings, declining ~6.0% from $228.15 to $214.53, suggesting the market has not rewarded the strong Q1 print and bullish bookings — this underperformance may reflect macro uncertainty or sector rotation, but creates a potentially favorable setup heading into Q2 if results confirm management’s top-of-range trajectory.

DOV vs XLI vs S&P 500 — Indexed Price Since Q1 2026 Earnings (Apr 23, 2026). Source: Yahoo Finance.

Key events: (1) May 12, 2026 — Shareholders rejected independent board chair proposal (governance-only, no financial impact). (2) June 16, 2026 — DOV announced Q2 2026 earnings release date of July 23, 2026.

DOV’s underperformance since Q1 earnings is notable given the strong print and bullish management tone. The stock initially rallied on Q1 earnings day but has since given back gains and then some, likely reflecting broader industrial sector rotation and macro uncertainty rather than company-specific deterioration. The underperformance vs. XLI is particularly striking given that several DOV peers (ETN, AME) have seen strong stock performance driven by AI/data center demand — DOV’s exposure to these same themes (heat exchangers for liquid cooling, $1B+ AI/power revenue target for 2026) has not been similarly rewarded. This creates a potentially asymmetric setup: if Q2 confirms the bookings-to-revenue conversion and management raises top-line guidance as telegraphed, the stock could re-rate meaningfully.

6. Material News & Developments

Key Takeaway: The most material development since Q1 earnings is the absence of any negative news — no guidance cuts, no order cancellations, no macro deterioration flagged — while peer commentary from ETN, AME, EMR, and others confirms robust demand in DOV’s key secular growth markets.

• July 23, 2026 — Q2 2026 Earnings Release (Before Market Open): Dover will report Q2 2026 results at 7:00 AM ET, followed by a conference call at 9:30 AM ET. Consensus expects $2.46 adjusted EPS and $2.21B revenue. Management has telegraphed driving to the top end of full-year guidance.
• June 16, 2026 — Q2 Earnings Date Announced: Dover officially confirmed July 23 as the Q2 2026 earnings release date. No financial updates were provided.
• May 12, 2026 — Shareholder Vote: Shareholders rejected a proposal to require an independent board chair (54% against). Governance-only event; no financial implications.
• April 23, 2026 — Q1 2026 Earnings (Last Print): Record bookings of $2.5B (+24% YoY), book-to-bill 1.2x across all five segments. Adjusted EPS of $2.03 beat consensus of $2.02. Revenue of $2.05B beat consensus of $2.00B. Management explicitly stated they are “driving to the top end of the range” and will revisit top-line guidance next quarter if bookings trends hold. April bookings confirmed “fine.”
• Ongoing — AI/Data Center Demand Acceleration: Multiple peers (ETN, AME, IEX, RRX) confirmed accelerating data center and AI-related demand in their Q1/Q2 2026 earnings calls. ETN reported data center orders up 240% and raised organic growth guidance by 200 bps. This is a direct read-through for DOV’s Climate & Sustainability Technologies (heat exchangers for liquid cooling) and Pumps & Process Solutions segments, and supports DOV’s $1B+ AI/power revenue target for 2026.
• Ongoing — Biopharma Recovery: EMR highlighted life sciences as a key growth vertical with GLP-1 production wins; IEX noted pharma as an area of strength with double-digit order growth; IR reported double-digit organic order growth in life sciences. This is a positive read-through for DOV’s Pumps & Process Solutions segment (single-use biopharma components), which lapped a tough comp in Q1 2026.
• Ongoing — Retail Fueling Cycle: DOV’s Clean Energy & Fueling segment grew 11% organically in Q1, driven by aggressive national retailer build-outs. Management characterized this as “still in the early innings of a multi-year growth cycle.” No peer commentary directly addresses this market, but the thesis remains intact.
• No analyst rating changes or price target revisions were identified in the post-Q1 earnings period through July 22, 2026.

7. Peer Commentaries — Q2 2026 Read-Throughs (Last 60 Days)

Key Takeaway: Peer commentary from Q1 2026 earnings calls (reported April 28 – May 21, 2026) is broadly positive for DOV’s key end markets — data centers/AI, biopharma, aerospace & defense, and general industrial recovery — with the most relevant signals coming from ETN (data center demand acceleration), AME (record bookings, broad-based strength), EMR (biopharma/LNG/power growth), and RRX (data center and medical strength). The one cautionary note is EMR’s Middle East conflict impact, which is not material for DOV given its limited exposure.

Note: All peers below reported AFTER DOV’s Q1 2026 earnings on April 23, 2026. Only forward-looking commentary about the April–June 2026 quarter (DOV’s Q2 2026) is included.

Eaton (ETN) — Q1 2026 Earnings (Reported May 5, 2026)

Relevance to DOV: High — ETN’s electrical/data center business is a direct read-through for DOV’s Climate & Sustainability Technologies (heat exchangers for liquid cooling) and Pumps & Process Solutions (AI/power infrastructure components). ETN also competes in some industrial end markets.

• Data Center Demand Surge: ETN reported data center orders up 240% in Q1 2026, with total electrical backlog up 48% YoY. Management stated “demand continues to surge, providing tremendous visibility.” The total data center backlog grew to 228 gigawatts (12 years of backlog at 2025 build rates). This is a strong positive read-through for DOV’s heat exchanger business (liquid cooling for data centers) and its $1B+ AI/power revenue target for 2026.
• Q2 Outlook Bullish: ETN stated “April was another strong month” for both sales and margins, and that “Q1 will be the trough” with “progress as we enter Q2 and momentum in Q3 and Q4.” Electrical Americas margins expected to improve 150 bps from Q1 to Q2. Positive read-through for DOV’s sequential improvement trajectory.
• Organic Growth Guidance Raised +200 bps: ETN raised full-year organic growth guidance to a midpoint of 10%, with Electrical Americas and Electrical Global both up 300 bps at the midpoint. This signals broad-based industrial demand strength that benefits DOV’s diversified portfolio.
• Tariff Impact Immaterial: ETN characterized tariff impacts as “immaterial” to full-year guidance — consistent with DOV’s “net neutral” tariff assessment and build-in-region manufacturing model.
• Mega Projects Accelerating: Mega project announcements up 29% YoY in Q1, with backlog of ~$3.3 trillion (+31% YoY). Mega project starts reached $54B in Q1, more than double the same period last year. This supports DOV’s longer-cycle infrastructure exposure.

AMETEK (AME) — Q1 2026 Earnings (Reported April 30, 2026)

Relevance to DOV: High — AME’s record bookings and broad-based order strength across defense, power, semiconductor, and medical markets are direct read-throughs for DOV’s Engineered Products (A&D), Pumps & Process Solutions (biopharma, energy infrastructure), and Climate & Sustainability Technologies segments.

• Record Bookings, No Pull-Forward: AME reported record Q1 orders of $2.2B (+23% YoY, +22% organic), with a record backlog of $3.87B. CEO David Zapico stated “March was an all-time record of any quarter for orders at AMETEK” and “April is on target for another good month.” Critically, CEO explicitly stated “I don’t think there was much pull ahead at all” — suggesting the demand is genuine and sustainable into Q2. This is important context for DOV’s own record Q1 bookings.
• Q2 Guidance: Sales Up High Single Digits: AME guided Q2 2026 sales up high single digits YoY, with adjusted EPS of $1.96–$2.00 (+10–12% YoY). Full-year organic growth guidance raised to mid-single digits. Broad-based strength with every division up at least 5% and every subsegment showing double-digit organic order growth.
• Defense Strength: A&D Guidance Raised to ~10%: AME’s A&D business grew high single digits in Q1 with broad-based strength, and A&D organic growth guidance was raised to ~10% for the full year. This is a positive read-through for DOV’s Engineered Products segment (electronic warfare, signal intelligence).
• Industrial Inflection Confirmed: AME noted “the industrial economy at below 50 PMIs for an extended period of time — that’s changing.” This supports DOV’s expectation of broad-based organic growth across its portfolio in 2026.
• Power Demand Strong: Power subsegment delivered strong record-level orders, with demand across power generation, backup power, data center microgrids, and power simulation systems. Positive read-through for DOV’s energy infrastructure components.

Emerson Electric (EMR) — Q2 FY2026 Earnings (Reported May 5, 2026; forward guidance covers Apr–Jun 2026)

Relevance to DOV: Medium-High — EMR’s commentary on biopharma/life sciences, LNG, power, and process automation is relevant for DOV’s Pumps & Process Solutions segment. EMR’s Middle East impact is a cautionary note but DOV has minimal direct exposure.

• Biopharma/GLP-1 Win: EMR was selected by a major Indiana pharmaceutical manufacturer to support a 3-site production program for oral GLP-1s. Life sciences is one of EMR’s five core growth verticals, with the project funnel growing to $11.2B. This is a positive read-through for DOV’s single-use biopharma components business in Pumps & Process Solutions, which lapped a tough comp in Q1 2026 and is expected to recover through the year.
• Power/LNG Growth Verticals Accelerating: EMR’s power vertical saw orders up 23% in Q2 (Jan–Mar), with the project funnel growing driven by new power opportunities. LNG remains a key growth vertical (EMR won Train 4 and 5 expansion at Rio Grande LNG). This supports DOV’s energy infrastructure components and midstream compression exposure.
• Q3 (Apr–Jun 2026) Guidance: ~5% Underlying Growth: EMR guided Q3 FY2026 (April–June 2026) underlying sales growth of ~5%, with adjusted EPS of $1.65–$1.70. Mid-single-digit orders are expected to be sustainable through the remainder of 2026. North America expected to grow high single digits for the year.
• Middle East Caution (Not Material for DOV): EMR flagged a 1-point full-year impact from the Middle East conflict (customer sites running at ~75% capacity due to Strait of Hormuz disruption). DOV has minimal direct Middle East exposure, so this is not a material read-through for DOV specifically.
• Tariff Net Neutral: EMR expects a net neutral impact from tariff changes (IEEPA removal offset by Section 122/232 increases and freight costs) — consistent with DOV’s own tariff assessment.

Regal Rexnord (RRX) — Q1 2026 Earnings (Reported May 7, 2026)

Relevance to DOV: Medium — RRX’s commentary on data center, medical, and general industrial recovery is relevant for DOV’s Climate & Sustainability Technologies and Pumps & Process Solutions segments.

• April Orders Up 4.6% Daily; Data Center & Medical Particularly Strong: RRX reported enterprise orders up 4.6% on a daily basis in April, with AMC (Automation & Motion Control) orders up 14% daily YoY. Data center, aerospace & defense, discrete automation, and medical were “particularly strong.” Medical orders were up 53% in Q1 and remained strong in April — a positive read-through for DOV’s biopharma/medical exposure.
• Data Center Capex Momentum Confirmed: RRX’s new Texas facility for data center production is on track to begin producing by midyear. The switchgear funnel remains ~$600M. This confirms continued data center capex momentum into Q2.
• Residential HVAC Finding a Floor: RRX noted “tentative signs that residential HVAC markets are finding a floor,” with volumes now assumed down mid-single digits vs. high single digits previously. This is a modest positive read-through for DOV’s Climate & Sustainability Technologies refrigeration business.
• Section 232 Tariffs Creating Share Gain Opportunity: RRX noted that Section 232 tariff revisions are creating new share gain opportunities for their U.S.-manufactured motors business. This is consistent with DOV’s “net neutral” tariff assessment and potential competitive advantage from its build-in-region model.

IDEX Corporation (IEX) — Q1 2026 Earnings (Reported April 29, 2026)

Relevance to DOV: Medium — IEX’s commentary on pharma, water, semiconductor, and general industrial markets is relevant for DOV’s Pumps & Process Solutions and Engineered Products segments.

• Q2 Organic Growth Guided 3–4%; Full-Year Raised to 3–4%: IEX guided Q2 2026 organic growth of 3–4%, with adjusted EBITDA margin of 26.5–27% and adjusted EPS of $2.07–$2.12. Full-year organic growth guidance raised to 3–4% from 1–2% — a meaningful upward revision driven by HST (Health & Science Technologies) strength.
• Pharma Strength; HST Backlog Provides Visibility: IEX noted pharma as “an area of strength” in Q1, with HST organic orders up 17% YoY. The strong backlog build in HST “improves visibility to deliver continued solid growth for the balance of the year and into 2027.” This is a positive read-through for DOV’s single-use biopharma components.
• Semiconductor/AI Demand Continuing: IEX reported strong order activity in semiconductor manufacturing and data center applications (power generation, thermal management). The high-purity water component for semiconductor applications “flipped over” from a headwind to positive and growing. Supports DOV’s secular growth narrative.
• General Industrial Improving; Order Cadence Strengthening: IEX noted “signs of improvement” in general industrial end markets, with order cadence improving through Q1 (soft January, recovery in February, strong March, maintained in April). This is consistent with DOV’s expectation of broad-based portfolio growth in 2026.

Nordson (NDSN) — Q2 FY2026 Earnings (Reported May 21, 2026; covers Feb–Apr 2026 with forward guidance for May–Jul 2026)

Relevance to DOV: Medium — NDSN’s commentary on semiconductor/electronics demand and medical markets is relevant for DOV’s Pumps & Process Solutions and Climate & Sustainability Technologies segments.

• Semiconductor Cycle in “Early Stages”; Backlog Up 18% Organically: NDSN stated the semiconductor cycle is in its “early stages,” with overall backlog up 18% organically YoY and all three segments contributing. ATS (Advanced Technology Solutions) backlog showed double-digit growth, with over 50% of ATS now in semiconductor applications. Management expressed “high confidence in the midpoint” of guidance and stated that sustaining current demand trends in electronics could lead to the upper end. This broad-based strength is a positive read-through for diversified industrials like DOV.
• Medical Recovery Underway: NDSN noted medical end markets “steadily returning to normalized growth” with 8% growth in the quarter. Long-term drivers (aging population, biopharma, minimally invasive procedures) remain intact. This is a positive read-through for DOV’s biopharma exposure.
• Industrial Recovery Gradual but Consistent: NDSN’s IPS segment returned to “normalized growth” with 4% organic growth in H1, with plastics and industrial coating businesses “certainly improving.” This supports DOV’s expectation of gradual improvement in core polymer processing equipment.
• No Pull-Forward; Lead Times Normalizing: NDSN noted no “fundamental change in overall backlog timing” and no “1 year out orders,” indicating typical order patterns. Lead times have improved from 16–18 weeks to less than 7–8 weeks. This is consistent with DOV’s characterization of longer lead times in growth markets as demand-driven rather than pre-buying.

Peer Read-Through Summary

8. Insider Transaction Activity

Key Takeaway: No open-market insider transactions (Form 4 buys or sells) were identified for DOV in the period from April 23 to July 22, 2026 — neither a bullish nor bearish signal, but the absence of insider buying ahead of what management described as a strong setup is worth noting.

No Form 4 open-market purchases or sales were filed by DOV insiders between April 23, 2026 (Q1 earnings) and July 22, 2026. The absence of insider buying is not unusual for a company in a quiet period ahead of earnings, but the lack of any discretionary purchases despite management’s explicitly bullish tone on the Q1 call is a neutral-to-slightly-cautious signal. No 10b5-1 plan initiations or Form 144 filings were identified in this period.